Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, Paris, France.
Laval University, Québec City, Québec, Canada.
Arthritis Care Res (Hoboken). 2024 Dec;76(12):1626-1636. doi: 10.1002/acr.25408. Epub 2024 Sep 4.
Treat-to-target is recommended in the management of rheumatoid arthritis (RA) but its implementation is suboptimal. We aimed to identify interventional strategies targeted at improving treat-to-target implementation in RA by systematically reviewing published evidence on barriers to, facilitators of, and interventions to support treat-to-target implementation.
Systematic and scoping literature searches in PubMed/MEDLINE, BIOSIS Previews, Derwent Drug File, Embase, EMCare, International Pharmaceutical Abstracts, and SciSearch were conducted to identify barriers/facilitators and interventions relating to treat-to-target implementation in RA. The quality of included studies was assessed using Critical Appraisal Skills Programme (CASP) checklists. Data related to barriers/facilitators and interventions were extracted, grouped, and summarized descriptively, and a narrative synthesis was generated.
In total, 146 articles were analyzed, of which 123 (84%) included ≥50% of the items assessed by CASP checklists. Of the 146 studies, 76 evaluated treat-to-target barriers and facilitators, from which 329 relevant statements were identified and regrouped into 18 target areas, including health care professional (HCP) or patient knowledge or perceptions; patient-HCP communication or alignment; and time or resources. Overall, 56 interventions were identified from 70 studies across the 18 target areas; 54% addressed disease activity or patient-reported outcome assessments. Of the 56 interventions identified, 36 improved treat-to-target implementation and/or patient outcomes in RA.
Despite long-established treat-to-target recommendations, there remain many barriers to its implementation. Interventions to improve treat-to-target should be developed further and assessed, with a particular focus on tailoring them to individual countries, regions, and health care settings.
针对类风湿关节炎(RA)的治疗目标推荐了靶向治疗,但实施情况并不理想。本研究旨在通过系统综述已发表的有关实现 RA 靶向治疗的障碍、促进因素和干预措施的证据,确定改善靶向治疗实施的干预策略。
在 PubMed/MEDLINE、BIOSIS Previews、Derwent Drug File、Embase、EMCare、International Pharmaceutical Abstracts 和 SciSearch 中进行了系统和范围广泛的文献检索,以确定与 RA 靶向治疗实施相关的障碍/促进因素和干预措施。使用关键评估技能计划(CASP)检查表评估纳入研究的质量。提取并分组总结与障碍/促进因素和干预措施相关的数据,并进行叙述性综合。
共分析了 146 篇文章,其中 123 篇(84%)文章包含 CASP 检查表评估的≥50%项目。在这 146 项研究中,有 76 项评估了靶向治疗的障碍和促进因素,从中确定了 329 项相关陈述,并将其重新分组为 18 个目标领域,包括医疗保健专业人员(HCP)或患者的知识或看法;患者-HCP 沟通或一致性;以及时间或资源。总体而言,从 18 个目标领域的 70 项研究中确定了 56 项干预措施;54%的干预措施针对疾病活动或患者报告的结果评估。在确定的 56 项干预措施中,有 36 项干预措施改善了 RA 中的靶向治疗实施和/或患者结局。
尽管有长期确立的靶向治疗建议,但仍存在许多实施障碍。应进一步开发和评估改善靶向治疗的干预措施,并特别关注针对个别国家、地区和医疗保健环境的干预措施。